Measurement of Whole Blood Tacrolimus Concentrations by LC-MS/MS and Immunoassay Methods: Influence of Immediate-Release vs Extended-Release Tacrolimus Formulations
The Journal of Applied Laboratory Medicine · 2025
DOI: 10.1093/jalm/jfae156 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von Adekunle Alabi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, UC San Diego Health, La Jolla, CA, United States. Hauptthemen laut MEDLINE: Tacrolimus, Tandem Mass Spectrometry, Drug Monitoring, Immunosuppressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Therapeutic drug monitoring of the immunosuppressant tacrolimus is commonly performed by immunoassay or LC-MS/MS. Measurement biases between these methodologies have been characterized for immediate-release tacrolimus (IR-tac; Prograf) but have not been performed for extended-release formulations such as Envarsus. These discrepancies can impact patient care, as appropriate dosing is required to maintain therapeutic concentrations and immunosuppression.
Methods
Validation of a whole-blood LC-MS/MS method for the simultaneous quantification of tacrolimus and its major metabolite, desmethyl tacrolimus, was performed using traceable calibrators (tacrolimus, ERM-DA110a) and quality control (QC) material for tacrolimus and standard material for desmethyl tacrolimus. Tacrolimus concentrations were determined by LC-MS/MS and the ARCHITECT immunoassay in patients receiving either IR-tac or Envarsus for clinical care.
Results
External calibration curves for both tacrolimus and desmethyl tacrolimus were linear (R2 > 0.995), and the analytical measurement range (AMR) for tacrolimus spanned from 1.1 to 31.6 ng/mL. Calibrator/QC biases were within 15% of their spiked concentrations throughout the AMR, and within-run imprecision was <10%, except at the lower limit of quantification (n = 25). Between-run imprecision for low, mid, and high QC levels was ≤11% over a 2-week period (n = 5 days). Comparative biases between immunoassay and LC-MS/MS were significantly lower (P = 0.0074) for patients receiving Envarsus (n = 20 specimens) relative to patients receiving IR-tac (n = 32 specimens).
Conclusions
Biases between immunoassay and LC-MS/MS tacrolimus measurements in patients receiving immediate-release vs extended-release formulations indicate that their distinct pharmacokinetic profiles impact measurement accuracy. These assay biases should be considered when interpreting tacrolimus concentration measurements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, UC San Diego Health, La Jolla, CA, United States.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego Health, La Jolla, CA, United States.
Zitieren
APA
Alabi, A., Ge, M., Momper, J. D., Tsunoda, S. M., Kelner, M. J., Fitzgerald, R. L., & Suhandynata, R. T. (2025). Measurement of Whole Blood Tacrolimus Concentrations by LC-MS/MS and Immunoassay Methods: Influence of Immediate-Release vs Extended-Release Tacrolimus Formulations. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae156
Vancouver
Alabi A, Ge M, Momper JD, Tsunoda SM, Kelner MJ, Fitzgerald RL, et al. Measurement of Whole Blood Tacrolimus Concentrations by LC-MS/MS and Immunoassay Methods: Influence of Immediate-Release vs Extended-Release Tacrolimus Formulations. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfae156
BibTeX
@article{Alabi2025,
author = {Alabi, Adekunle and Ge, Mengyuan and Momper, Jeremiah D and Tsunoda, Shirley M and Kelner, Michael J and Fitzgerald, Robert L and Suhandynata, Raymond T},
title = {Measurement of Whole Blood Tacrolimus Concentrations by LC-MS/MS and Immunoassay Methods: Influence of Immediate-Release vs Extended-Release Tacrolimus Formulations},
journal = {The Journal of Applied Laboratory Medicine},
year = {2025},
doi = {10.1093/jalm/jfae156}
}
EUVIMED